Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$44.72
-5.7%
$52.30
$16.96
$73.00
$1.23B1.22379,970 shs209,922 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$21.54
-0.6%
$20.52
$7.41
$24.17
$1.64B0.941.12 million shs153,507 shs
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
$23.94
$23.89
$15.23
$23.98
$1.61B0.77659,586 shsN/A
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
$94.50
-0.6%
$102.23
$78.08
$124.11
$1.42B1.468,188 shs34,883 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
+1.80%-11.99%-15.59%-1.74%-32.87%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+0.88%-0.50%+5.19%-1.36%+70.44%
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
0.00%0.00%0.00%0.00%+45.62%
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
-0.05%-3.96%-9.42%-10.81%-13.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
0.9926 of 5 stars
2.41.00.00.03.42.50.6
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3.3356 of 5 stars
3.41.00.04.73.40.80.0
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
N/AN/AN/AN/AN/AN/AN/AN/A
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
4.0182 of 5 stars
3.54.02.50.03.00.82.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.80
Moderate Buy$56.0025.22% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$28.3631.65% Upside
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
2.00
Hold$22.98-4.01% Downside
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
3.00
Buy$125.6732.98% Upside

Current Analyst Ratings

Latest NXGN, USPH, ESTA, and KURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2024
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $70.00
5/22/2024
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$60.00 ➝ $60.00
5/16/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/14/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
5/9/2024
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$122.00 ➝ $122.00
5/6/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/3/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
5/3/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00
4/22/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
4/3/2024
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$49.00 ➝ $60.00
4/1/2024
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $65.00
(Data available from 6/13/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$165.15M7.45N/AN/A$0.71 per share62.99
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/A$5.35 per shareN/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
$653.17M2.46$1.16 per share20.57$6.31 per share3.79
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
$611.97M2.33$4.59 per share20.58$31.85 per share2.97

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$78.50M-$3.14N/AN/AN/A-53.12%-206.05%-29.39%8/13/2024 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$152.63M-$2.17N/AN/AN/AN/A-37.52%-34.11%8/1/2024 (Estimated)
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
-$2.65M-$0.10N/A27.52N/A-0.89%11.37%5.38%N/A
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
$28.24M$1.2376.8329.913.664.72%8.03%3.88%8/13/2024 (Estimated)

Latest NXGN, USPH, ESTA, and KURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.65-$0.58+$0.07-$0.58$35.61 million$37.17 million    
5/7/2024Q1 2024
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
$0.58$0.51-$0.07$0.56$153.30 million$155.70 million    
5/2/2024Q1 2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.56-$0.59-$0.03-$0.59N/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
N/AN/AN/AN/AN/A
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
$1.761.86%+75.17%143.09%N/A

Latest NXGN, USPH, ESTA, and KURA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2024
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
Quarterly$0.441.69%5/22/20245/23/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
3.38
4.24
2.73
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
16.67
16.67
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
0.63
2.52
2.52
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
0.28
2.16
2.16

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
72.91%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
76.65%
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
N/A

Insider Ownership

CompanyInsider Ownership
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
11.44%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
5.50%
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
4.60%
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
1.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
90827.51 million24.37 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
14276.18 million71.99 millionOptionable
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
2,78367.10 million64.01 millionOptionable
U.S. Physical Therapy, Inc. stock logo
USPH
U.S. Physical Therapy
6,72015.07 million14.81 millionOptionable

NXGN, USPH, ESTA, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Establishment Labs logo

Establishment Labs

NASDAQ:ESTA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Kura Oncology logo

Kura Oncology

NASDAQ:KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
NextGen Healthcare logo

NextGen Healthcare

NASDAQ:NXGN
NextGen Healthcare, Inc. provides healthcare technology solutions in the United States. The company offers clinical care solutions, including NextGen Enterprise EHR; financial solutions, such as NextGen Enterprise PM; patient engagement solutions comprising NextGen Virtual Visits; integrated clinical care and financial solutions consisting of NextGen Office; interoperability solutions that include NextGen Share and Mirth Connect; data and analytics solutions, which comprise NextGen Health Data Hub; and value based care solutions, including NextGen Population Health Solutions. It also provides managed services, such as revenue cycle management services comprising billing and collections, electronic claims submission and denials management, electronic remittance and payment posting, and accounts receivable follow-up; and client and support services. Further, the company offers professional services consisting of training, project management, installation services, and application managed services; and consulting services that include physician, professional, and technical consulting; assisting clients to optimize their staffing and software solutions; enhancing financial and clinical outcomes; achieving regulatory requirements; and meeting the requirements of healthcare reform. It serves accountable care organizations, independent physician associations, managed service organizations, veterans service organizations, dental service organizations, ambulatory care centers, and community health centers through a direct sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was incorporated in 1974 and is based in Atlanta, Georgia.
U.S. Physical Therapy logo

U.S. Physical Therapy

NYSE:USPH
U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas.